TY - JOUR
T1 - Clinical Outcomes of Hypertonic Saline vs Mannitol Treatment among Children with Traumatic Brain Injury
AU - The Pediatric Acute andCritical Care Medicine in Asia Network (PACCMAN)and the Red Colaborativa Pediátrica de Latinoamérica (LARed)
AU - Chong, Shu Ling
AU - Zhu, Yanan
AU - Wang, Quan
AU - Caporal, Paula
AU - Roa, Juan D.
AU - Chamorro, Freddy Israel Pantoja
AU - Teran Miranda, Thelma Elvira
AU - Dang, Hongxing
AU - Gan, Chin Seng
AU - Abbas, Qalab
AU - Ardila, Ivan J.
AU - Antar, Mohannad Ahmad
AU - Domínguez-Rojas, Jesús A.
AU - Rodríguez, María Miñambres
AU - Watzlawik, Natalia Zita
AU - Gómez Arriola, Natalia Elizabeth
AU - Yock-Corrales, Adriana
AU - Lasso-Palomino, Rubén Eduardo
AU - Xiu, Ming Mei
AU - Ong, Jacqueline S.M.
AU - Kurosawa, Hiroshi
AU - Aparicio, Gabriela
AU - Liu, Chunfeng
AU - Samransamruajkit, Rujipat
AU - Jaramillo-Bustamante, Juan C.
AU - Anantasit, Nattachai
AU - Chor, Yek Kee
AU - Turina, Deborah M.
AU - Lee, Pei Chuen
AU - Flores, Marisol Fonseca
AU - Pilar Orive, Francisco Javier
AU - Ng Pei Wen, Jane
AU - González-Dambrauskas, Sebastián
AU - Lee, Jan Hau
AU - Kazzaz, Yasser M.
AU - Jian, Ji
AU - Qian, Suyun
AU - Fan, Lijia
AU - Lee, Olive Pei Ee
AU - Chuah, Soo Lin
AU - You, Kai
AU - Zhang, Tao
AU - Noguera, Deiby Lasso
AU - Cerón, Esteban
AU - Barceló, Andrea Leal
AU - Domínguez, Susana Beatriz Reyes
AU - Ortega Ocas, Cesia J.
N1 - Publisher Copyright:
© 2025 Chong SL et al.
PY - 2025/3/11
Y1 - 2025/3/11
N2 - Importance: The use of hypertonic saline (HTS) vs mannitol in the control of elevated intracranial pressure (ICP) secondary to neurotrauma is debated. Objective: To compare mortality and functional outcomes of treatment with 3% HTS vs 20% mannitol among children with moderate to severe traumatic brain injury (TBI) at risk of elevated ICP. Design, Setting, and Participants: This prospective, multicenter cohort study was conducted between June 1, 2018, and December 31, 2022, at 28 participating pediatric intensive care units in the Pediatric Acute and Critical Care Medicine in Asia Network (PACCMAN) and the Red Colaborativa Pediátrica de Latinoamérica (LARed) in Asia, Latin America, and Europe. The study included children (aged <18 years) with moderate to severe TBI (Glasgow Coma Scale [GCS] score ≤13). Exposure: Treatment with 3% HTS compared with 20% mannitol. Main Outcomes and Measures: Multiple log-binomial regression analysis was performed for mortality, and multiple linear regression analysis was performed for discharge Pediatric Cerebral Performance Category (PCPC) scores and 3-month Glasgow Outcome Scale-Extended Pediatric Version (GOS-E-Peds) scores. Inverse probability of treatment weighting was also performed using the propensity score method to control for baseline imbalance between groups. Results: This study included 445 children with a median age of 5.0 (IQR, 2.0-11.0) years. More than half of the patients (279 [62.7%]) were boys, and 344 (77.3%) had severe TBI. Overall, 184 children (41.3%) received 3% HTS, 82 (18.4%) received 20% mannitol, 69 (15.5%) received both agents, and 110 (24.7%) received neither agent. The mortality rate was 7.1% (13 of 184 patients) in the HTS group and 11.0% (9 of 82 patients) in the mannitol group (P =.34). After adjusting for age, sex, presence of child abuse, time between injury and hospital arrival, lowest GCS score in the first 24 hours, and presence of extradural hemorrhage, no between-group differences in mortality, hospital discharge PCPC scores, or 3-month GOS-E-Peds scores were observed. Conclusions and Relevance: In this cohort study of children with moderate to severe TBI, the use of HTS was not associated with increased survival or improved functional outcomes compared with mannitol. Future large multicenter randomized clinical trials are required to validate these findings.
AB - Importance: The use of hypertonic saline (HTS) vs mannitol in the control of elevated intracranial pressure (ICP) secondary to neurotrauma is debated. Objective: To compare mortality and functional outcomes of treatment with 3% HTS vs 20% mannitol among children with moderate to severe traumatic brain injury (TBI) at risk of elevated ICP. Design, Setting, and Participants: This prospective, multicenter cohort study was conducted between June 1, 2018, and December 31, 2022, at 28 participating pediatric intensive care units in the Pediatric Acute and Critical Care Medicine in Asia Network (PACCMAN) and the Red Colaborativa Pediátrica de Latinoamérica (LARed) in Asia, Latin America, and Europe. The study included children (aged <18 years) with moderate to severe TBI (Glasgow Coma Scale [GCS] score ≤13). Exposure: Treatment with 3% HTS compared with 20% mannitol. Main Outcomes and Measures: Multiple log-binomial regression analysis was performed for mortality, and multiple linear regression analysis was performed for discharge Pediatric Cerebral Performance Category (PCPC) scores and 3-month Glasgow Outcome Scale-Extended Pediatric Version (GOS-E-Peds) scores. Inverse probability of treatment weighting was also performed using the propensity score method to control for baseline imbalance between groups. Results: This study included 445 children with a median age of 5.0 (IQR, 2.0-11.0) years. More than half of the patients (279 [62.7%]) were boys, and 344 (77.3%) had severe TBI. Overall, 184 children (41.3%) received 3% HTS, 82 (18.4%) received 20% mannitol, 69 (15.5%) received both agents, and 110 (24.7%) received neither agent. The mortality rate was 7.1% (13 of 184 patients) in the HTS group and 11.0% (9 of 82 patients) in the mannitol group (P =.34). After adjusting for age, sex, presence of child abuse, time between injury and hospital arrival, lowest GCS score in the first 24 hours, and presence of extradural hemorrhage, no between-group differences in mortality, hospital discharge PCPC scores, or 3-month GOS-E-Peds scores were observed. Conclusions and Relevance: In this cohort study of children with moderate to severe TBI, the use of HTS was not associated with increased survival or improved functional outcomes compared with mannitol. Future large multicenter randomized clinical trials are required to validate these findings.
UR - https://www.scopus.com/pages/publications/105000204275
U2 - 10.1001/jamanetworkopen.2025.0438
DO - 10.1001/jamanetworkopen.2025.0438
M3 - Article
C2 - 40067302
AN - SCOPUS:105000204275
SN - 2574-3805
VL - 8
JO - JAMA network open
JF - JAMA network open
IS - 3
M1 - e250438
ER -